Cell therapy weekly: Eureka Therapeutics and the National Cancer Institute enter license agreement to progress development of T-cell therapy for neuroblastoma
This week: Eureka Therapeutics and the National Cancer Institute enter license agreement to progress development of T-cell therapy for neuroblastoma, Charles River and Nanoscope Therapeutics announce gene therapy manufacturing partnership and Thermo Fisher Scientific launch closed and automated cell isolation and bead removal solution for cell therapy manufacture
The news highlights:
-
-
-
-
- Eureka Therapeutics and the National Cancer Institute enter license agreement to progress development of T-cell therapy for neuroblastoma
- Charles River and Nanoscope Therapeutics announce gene therapy manufacturing partnership
- Thermo Fisher Scientific launch closed and automated cell isolation and bead removal solution for cell therapy manufacture
-
-
-
Eureka Therapeutics and the National Cancer Institute enter license agreement to progress development of T-cell therapy for neuroblastoma
Eureka Therapeutics (CA, USA), a clinical-stage biotechnology company focusing on the development of novel T-cell therapies to treat cancer, has announced it has entered into a license agreement with the National Cancer Institute (MD, USA) for a glypican 2 (GPC2) binding domain. Eureka Therapeutics will utilize this for the potential development and subsequent commercialization of ARTEMIS® T-cell therapies to treat neuroblastoma, a rare cancer affecting the developing nervous system. This therapy also has the potential to treat several other pediatric and adult cancers that express an abundance of the GPC2 protein.
“GPC2 is an exciting new target for neuroblastoma. In pre-clinical models, anti-GPC2 directed ARTEMIS T cells demonstrated significant tumor-killing activity,” said Mitchell Ho, Deputy Chief of the Laboratory of Molecular Biology and Director of the Antibody Engineering Program at the National Cancer Institute Center for Cancer Research. “We believe it is beneficial to further evaluate anti-GPC2 directed ARTEMIS T-cells as a potential T-cell therapy for patients with neuroblastoma and other cancers that express GPC2.”
Charles River and Nanoscope Therapeutics announce gene therapy manufacturing partnership
Charles River Laboratories (MA, USA) and Nanoscope Therapeutics (TX, USA) announced they have entered a gene therapy manufacturing collaboration. The partnership will grant Nanoscope Therapeutics, a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, access to Charles River’s contract development and manufacturing services in both GMP-grade plasmid DNA manufacture and GMP adeno-associated virus production.
Kerstin Dolph, corporate Senior Vice President of Biologics Solutions at Charles River stated: “We are excited to continue to support Nanoscope Therapeutics’ efforts in the production of gene therapies that are focused on restoring vision for people suffering from retinal degenerative diseases with no known cure. Their work is incredibly important to patients, and we look forward to continuing to serve as a partner.”
Thermo Fisher Scientific launch closed and automated cell isolation and bead removal solution for cell therapy manufacture
Thermo Fisher Scientific (MA, USA) unveiled the Gibco™ CTS™ DynaCellect™ Magnetic Separation System, a closed, automated isolation, activation, and bead removal system for cell therapy development and manufacturing. This new technology improves cell purity and isolation efficiency and increases recovery of target cells for scalable cell therapy manufacturing.
Vice President and General Manager of cell culture and cell therapy at Thermo Fisher Scientific, Tiffani Manolis stated: “The future of cell therapy is bright, and our team is focused on innovations that expedite breakthroughs and, ultimately, help patients. DynaCellect helps minimize the potential for errors while accelerating the manufacturing process. This allows our customers to commercialize therapies faster and potentially save more lives. It is a perfect example of how our innovations deliver on our commitment to helping our customers make the world healthier.”
You might also like:
- Cell therapy weekly: Kite’s viral vector manufacturing facility receives FDA approval to produce commercial products
- Cell therapy weekly: Scribe Therapeutics and Sanofi collaborate to accelerate CRISPR-based cell therapies for cancer
- Cell therapy weekly: Forge Biologics secure US$90 million in Series C funding